MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

New Processing Assemblies Deliver Increased Flexibility, Efficiency, and Ease of Cell Recovery

NK Cells: The Latest Recruits in the Battle Against Cancer

Don’t Settle for Just Your Average CHO and Other Cell Line Development Advances

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe

MaxCyte CEO Doug Doerfler to Present at ARM’s 7th Annual Cell & Gene Therapy Investor Day

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company

MaxCyte: Driving New Generation of Cell-Based Medicines

Hitachi Chemical Advanced Therapeutics Solutions Completes Technology Transfer to Enable Manufacturing of MaxCyte’s CARMA™ Cell Therapy for Clinical Use

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019

MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference

Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease

MaxCyte, Inc. to Present at 2018 BIO International Convention

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month

Dr. Richard Douglas Joins MaxCyte Board

MaxCyte, Inc. to Present at Two Life Sciences Conferences

MaxCyte, Inc. to Present at Phacilitate’s Cell & Gene Therapy Europe Conference

MaxCyte Appoints Executive Vice President of Global Marketing

MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy

MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with Maxcyte

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting

MaxCyte, Inc. to Present at Phacilitate Cell & Gene Therapy World Conference

MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene

MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies

MaxCyte Appoints Executive Vice President, Business and Strategic Development

MaxCyte, Inc. to Present at 2016 Cell & Gene Meeting on the Mesa and Biotech Week Boston 2016

MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems

MaxCyte Announces a CRADA with US Army Medical Research Institute of Infectious Diseases for an Exploratory Research Collaboration on Rapid Response Medical Countermeasures

MaxCyte to Present Gene Editing Results at the American Society of Gene and Cell Therapy Annual Meeting

MaxCyte Partner to Present Data at the Inaugural Bioprocess International West Conference

MaxCyte to Present Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection

MaxCyte Partners to Present Data at Annual Biophysical Society Meeting

MaxCyte, Inc. to Present at Biotech Showcase 2016

MaxCyte Appoints Spinco Biotech Pvt Ltd. as Distributor in India for the MaxCyte STX® and MaxCyte VLX®

MaxCyte to present novel approach to CAR-T for treatment of solid tumors at Biochemical Society in London

MaxCyte, Inc. to Present at 2015 Immuno-Oncology Conference

MaxCyte to Present New Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection

MaxCyte Appoints Chayon Laboratories as Distributor in Korea for the MaxCyte STX® and MaxCyte VLX®

MaxCyte to Present Data on the Ability of Flow Electroporation to Streamline Antibody Development and Production

MaxCyte Awarded Maryland Stem Cell Research Fund Grant

MaxCyte to Present Data on Development of ‘Enhanced’ Potency Cell Therapy Products

MaxCyte and Partners to Present Data at American Society of Gene and Cell Therapy Meeting

MaxCyte to Present Data on Achieving 2.7 grams/Liter of Antibody in CHO Cells With Flow Electroporation

MaxCyte Appoints Cold Spring Biotech Corp. as Distributor in China, Taiwan, and Hong Kong for the MaxCyte STX® and MaxCyte VLX®

MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies

MaxCyte to Present at the 2015 Jefferies Immuno-Oncology Summit

MaxCyte Publishes Data on Gram/Liter Antibody Production in the Journal of Biomolecular Screening

MaxCyte to Present at 3rd Annual Regen Med Investor Day

MaxCyte to Present Data Demonstrating the Impact of Flow Transfection on Improving Protein Expression

MaxCyte Appoints Executive Vice President of Global Sales

Accelerating Product Development: From Transient Transfection to Stable Pools and Stable Clones

MaxCyte Introduces Rapid, Automated, Scalable Flow Electroporation-based Technology for Vaccine Development

MaxCyte Introduces the 2014 MaxCyte STX® Scalable Transfection System at CHI’s 13th Annual PepTalk Conference in Palm Springs, Booth #308